WallStreetZenWallStreetZen

NYSE: PEN
Penumbra Inc Stock Forecast, Predictions & Price Target

Analyst price target for PEN

Based on 11 analysts offering 12 month price targets for Penumbra Inc.
Min Forecast
$163.00-37.23%
Avg Forecast
$238.36-8.21%
Max Forecast
$285.00+9.75%

Should I buy or sell PEN stock?

Based on 11 analysts offering ratings for Penumbra Inc.
Strong Buy
Strong Buy
9 analysts 81.82%
Buy
2 analysts 18.18%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PEN stock forecasts and price targets.

PEN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
JP Morgan
Top 17%
84
Strong BuyMaintains$285.00+9.75%2023-02-01Find out why
BTIG
Top 2%
99
Strong BuyMaintains$270.00+3.97%2023-01-30Find out why
Piper Sandler
Bottom 6%
6
Strong BuyInitiates Coverage On$275.00+5.90%2023-01-30
Truist Securities
Top 35%
66
Strong BuyMaintains$255.00-1.81%2022-12-20
Wells Fargo
Top 9%
92
Strong BuyMaintains$255.00-1.81%2022-12-12
Citigroup
Top 6%
95
Strong BuyMaintains$270.00+3.97%2022-12-12Find out why
Needham
Bottom 1%
1
BuyMaintains$235.00-9.51%2022-11-04
Jefferies
Top 17%
84
Strong BuyInitiates Coverage On$230.00-11.43%2022-10-12
Canaccord Genuity
Bottom 10%
10
Strong BuyMaintains$189.00-27.22%2022-08-05
Deutsche Bank
Top 32%
69
Strong BuyMaintains$163.00-37.23%2022-07-21

1 of 2

Forecast return on equity

Is PEN forecast to generate an efficient return?
Company
7.25%
Industry
16.1%
Market
47.78%
PEN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PEN forecast to generate an efficient return on assets?
Company
5.35%
Industry
10.41%
PEN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PEN earnings per share forecast

What is PEN's earnings per share in the next 2 years based on estimates from 4 analysts?
Avg 1 year Forecast
$1.13
Avg 2 year Forecast
$1.86

PEN revenue forecast

What is PEN's revenue in the next 2 years based on estimates from 4 analysts?
Avg 1 year Forecast
$1.0B+21.66%
Avg 2 year Forecast
$1.2B+39.44%
PEN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PEN revenue growth forecast

How is PEN forecast to perform vs Medical Devices companies and vs the US market?
Company
21.66%
Industry
10.85%
Market
72.18%
PEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PEN vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
PEN$259.69$238.36-8.21%Strong Buy
BRKR$71.50$79.00+10.49%Strong Buy
GMED$76.90$75.33-2.04%Strong Buy
SNN$28.32$34.50+21.82%Buy
INSP$243.99$291.20+19.35%Strong Buy

Penumbra Stock Forecast FAQ

Is Penumbra Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 11 Wall Street analysts covering (NYSE: PEN) stock is to Strong Buy PEN stock.

Out of 11 analysts, 9 (81.82%) are recommending PEN as a Strong Buy, 2 (18.18%) are recommending PEN as a Buy, 0 (0%) are recommending PEN as a Hold, 0 (0%) are recommending PEN as a Sell, and 0 (0%) are recommending PEN as a Strong Sell.

If you're new to stock investing, here's how to buy Penumbra stock.

What is PEN's earnings growth forecast for 2023-2024?

(NYSE: PEN) Penumbra's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 92.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 85.2%.

Penumbra's earnings in 2023 is -$30,512,000.On average, 4 Wall Street analysts forecast PEN's earnings for 2023 to be $42,915,710, with the lowest PEN earnings forecast at $32,661,513, and the highest PEN earnings forecast at $58,486,896.

In 2024, PEN is forecast to generate $70,640,017 in earnings, with the lowest earnings forecast at $66,842,167 and the highest earnings forecast at $74,058,083.

What is PEN's revenue growth forecast for 2023-2024?

(NYSE: PEN) Penumbra's forecast annual revenue growth rate of 21.66% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 10.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 72.18%.

Penumbra's revenue in 2023 is $829,928,000.On average, 4 Wall Street analysts forecast PEN's revenue for 2023 to be $38,346,515,704, with the lowest PEN revenue forecast at $38,088,261,877, and the highest PEN revenue forecast at $38,472,224,552.

In 2024, PEN is forecast to generate $43,950,243,969 in revenue, with the lowest revenue forecast at $43,518,808,164 and the highest revenue forecast at $44,381,679,774.

What is PEN's forecast return on assets (ROA) for 2023-2024?

(NYSE: PEN) forecast ROA is 5.35%, which is lower than the forecast US Medical Devices industry average of 10.41%.

What is PEN's Price Target?

According to 11 Wall Street analysts that have issued a 1 year PEN price target, the average PEN price target is $238.36, with the highest PEN stock price forecast at $285.00 and the lowest PEN stock price forecast at $163.00.

On average, Wall Street analysts predict that Penumbra's share price could fall to $238.36 by Feb 1, 2024. The average Penumbra stock price prediction forecasts a potential downside of 8.21% from the current PEN share price of $259.69.

What is PEN's Earnings Per Share (EPS) forecast for 2023-2024?

(NYSE: PEN) Penumbra's current Earnings Per Share (EPS) is -$0.84. On average, analysts forecast that PEN's EPS will be $1.13 for 2023, with the lowest EPS forecast at $0.86, and the highest EPS forecast at $1.54. In 2024, PEN's EPS is forecast to hit $1.86 (min: $1.76, max: $1.95).

What is PEN's forecast return on equity (ROE) for 2023-2024?

(NYSE: PEN) forecast ROE is 7.25%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.